Onco Actu du 22 juin 2017

	2.5 Etiologie - Gènes
Seven new DNA regions linked to kidney cancer risk [Institute of Cancer Research] People with these variants are more likely to develop renal cell carcinoma, through the effect they have on nearby genes.
Genes that affect diseases and other traits may be scattered across genome [Stanford Medicine] Pritchard and colleagues published a paper in Cell suggesting that the bulk of the inheritance of complex traits comes not from those few dozen “core genes” but from thousands of gene variants scattered across the genome.
Thinking About Genetics and Disease [In the Pipeline] People – managers, investors, reporters, doctors, the general public – get tired of hearing “Gosh, it’s more complicated than it looks, we have to do more work”. But all of this stuff really is more complicated than it looks...
	5. Traitements
New Antibody Uses One-Two Punch to Potentially Treat Blood Cancers [ASH] The findings of multiple in vivo preclinical studies published online today in BloodAdvances, a Journal of the American Society of Hematology (ASH), indicate that this therapy could potentially treat multiple cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and acute myeloid leukemia (AML).
	5.12 Immunothérapies
First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients [OSU] “This study is an important step toward understanding the impact of tumor mutation burden and PDL-1 in immunotherapy response. This data shows we should evaluate these two factors independently to most accurately define who will benefit from immunotherapy,” says Carbone.
	5.12.5 Immunothérapies - Pharma
Cash-strapped ImmunoCellular halts brain cancer vaccine trial, eyes 'strategic alternatives' [FierceBiotech] Things have not always gone smoothly with the development of ICT-107, a dendritic cell-based immunotherapy in development for glioblastoma, the most common and deadly form of brain cancer.
Running out of cash and cited on fraud charges, ImmunoCellular retreats on PhIII and cries for help [EndPoints] ICT-107 hit the radar in late 2013 when the company conceded that their drug— a dendritic cell vaccine— had failed to improve the overall survival rate of brain cancer patients in Phase II.
	5.2 Pharma
Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego [Lilly] New facility and improved technology capabilities part of $850 million U.S. capital investment for 2017.
	5.2.2 Pharma - Fusions & Acquisitions
Biopharma Outsourcing Is Going Through Deal Bonanza in U.S. [Bloomberg] Contract research organizations -- the science-for-hire firms that handle clinical trials, medical-lab testing and other services for pharmaceutical companies -- are all the talk of the health-care M&A world. The latest transaction was the $4.5 billion takeout of Parexel International Corp. on Tuesday. And analysts say there’s more to come.
	5.2.3 Pharma - économie
Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP [Xconomy] Repare, based in Boston and Montreal, is looking beyond PARP for other targets that would prevent cells from repairing their own DNA. “We’re grateful to PARPs for having proved the case,” says Repare CEO Lloyd Segal. “But we think this is just the tip of the iceberg.”
Top 20 blockbuster drugs in the late-stage pipeline — EvaluatePharma [EndPoints] AbbVie has 4 drugs in late-stage development that fall in the top 20, more than any other company on the list.
	5.3 Traitements - FDA, EMA, NICE...
Gottlieb’s FDA to rethink targeted therapy regulation to speed development, drive down healthcare costs [FierceBiotech] The commissioner presented the plan alongside internal changes at the FDA designed to speed the development of rare disease drugs.
A Meeting to Discuss FDA’s Continuing Conundrum: Innovation vs. Access [FDA Law Blog] The meeting is intended to further explore the juxtaposition of innovation in drug development and access to lower cost alternatives to innovator drugs.
Landmark FDA approval bolsters personalized medicine [STAT] While the regulatory landscape for these targeted medicines is clear, the path to market for the molecular tests that do the targeting is not
FDA Working to Lift Barriers to Generic Drug Competition [FDA Voice] We know that sometimes our regulatory rules might be “gamed” in ways that may delay generic drug approvals beyond the time frame the law intended, in order to reduce competition. We are actively looking at ways our rules are being used and, in some cases, misused.
U.S. FDA moves to prevent Pharma from 'gaming' generic drug system [Reuters] The FDA does not include price considerations when deciding whether to approve a new drug, but Gottlieb said the agency can facilitate increased competition by approving lower-cost generics.
	5.9.3 EHA
Amgen To Present New Data At 22nd Congress of the European Hematology Association [Amgen] Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma.
	6. Lutte contre les cancers
8 new challenges between us and beating cancer [Cancer Research UK] So while our teams and others inspired by the first set of Grand Challenges are sinking their teeth into them, we’re now on the hunt for answers to a new collection.
First NHS proton beam machine arrives at Christie hospital [BBC News] Up to 750 patients will use the new unit due to open in August 2018.
	6.1 Observation
Air pollution tied to survival odds for liver cancer patients [Reuters] To see if there is a link between air pollution and liver cancer survival, the researchers used data on over 20,000 patients with the most common form of liver cancer, hepatocellular carcinoma.
	6.4 Médico-éco
Cheshire cancer patients 'could die sooner' if NHS cuts are forced through [The Guardian] Macmillan Cancer Support said the plan was “incredibly worrying for cancer patients”.